{"id":"NCT04973228","sponsor":"Arcutis Biotherapeutics, Inc.","briefTitle":"Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)","officialTitle":"A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-07-08","primaryCompletion":"2022-04-06","completion":"2022-04-06","firstPosted":"2021-07-22","resultsPosted":"2024-03-12","lastUpdate":"2024-03-12"},"enrollment":457,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Seborrheic Dermatitis"],"interventions":[{"type":"DRUG","name":"Roflumilast Foam","otherNames":["ARQ-154"]},{"type":"DRUG","name":"Vehicle Foam","otherNames":[]}],"arms":[{"label":"Roflumilast Foam 0.3%","type":"EXPERIMENTAL"},{"label":"Vehicle Foam","type":"PLACEBO_COMPARATOR"}],"summary":"This phase 3, double-blind, vehicle-controlled study assessed the safety and efficacy of roflumilast (ARQ-154) foam 0.3% applied once daily (qd) for 8 weeks by participants with seborrheic dermatitis.","primaryOutcome":{"measure":"Achievement of Success on the Investigator Global Assessment (IGA) at Week 8","timeFrame":"Week 8","effectByArm":[{"arm":"Roflumilast Foam 0.3%","deltaMin":80,"sd":null},{"arm":"Vehicle Foam","deltaMin":58,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":8},"locations":{"siteCount":53,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":304},"commonTop":[]}}